This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent adenocarcinoma of the ovary who have been previously treated with a minimum of two courses of platinum-based chemotherapy, and up to two additional cytotoxic regimens that may also have included platinum (no more than four total lines of prior therapy), with or without bevacizumab, whose cancer has recurred within six months of the most recent platinum-based chemotherapy. All eligible subjects will receive VAL 083 i.v. in a once weekly cycle until disease progression, development of other unacceptable toxicity, death, withdrawal of consent, loss to follow-up, or Sponsor ending the study, whichever occurs first.

Start Date01 Mar 2021

Sponsor / Collaborator

Kintara Therapeutics, Inc.

ChiCTR2000041279

/ RecruitingPhase 4IIT

A single-arm, multicenter, exploratory, post-marketing clinical study of evaluating desquaxel for injection in the second-line treatmen

Start Date01 Dec 2020

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

[+1]

ChiCTR2000039032

/ RecruitingEarly Phase 1IIT

A prospective, randomized, controlled trial of bortezomib combined with DAG regimen for refractory/relapsed AML

Start Date01 Jan 2020

Sponsor / Collaborator

Zhongnan hospital of wuhan university

100 Clinical Results associated with Dianhydrodulcitol

100 Translational Medicine associated with Dianhydrodulcitol

100 Patents (Medical) associated with Dianhydrodulcitol

324

Literatures (Medical) associated with Dianhydrodulcitol

01 Dec 2026·JOURNAL OF AFFECTIVE DISORDERS

Psychological stress-associated ceramide and diacylglyceride lipotoxicity as contributors to first-episode depression pathophysiology: A neuroimmune-metabolic-oxidative stress (NIMETOX) perspective

Article

Author: Tansawat, Rossarin ; Sirivatanapa, Visuthsiri ; Janta, Pannipa ; Carvalho, Andre F ; Almulla, Abbas F ; Maes, Michael ; Sriswasdi, Sira ; Zhang, Yingqian ; Tunvirachaisakul, Chavit ; Vasupanrajit, Asara

BACKGROUND:

Aberrations in neuro-immune, metabolic, and oxidative stress (NIMETOX) pathways are implicated in major depressive disorder (MDD). First-episode simple dysmood disorder (FE-SDMD) without metabolic syndrome offers a unique model to investigate early lipid alterations using a systems biology approach.

METHODS:

Plasma samples were collected from 88 university students (44 FE-SDMD, 44 healthy controls). Participants underwent psychiatric assessments, including adverse childhood experiences (ACEs), negative life events (NLEs), depression, anxiety, suicidal behaviors, and insomnia. Untargeted lipid profiling was performed using LC-QTOF-MS, while indices of oxidative and nitrosative stress (ONS) and lecithin-cholesterol acyltransferase (LCAT) activity were assessed. Data was analyzed using machine learning approaches with recursive feature elimination and cross-validation.

RESULTS:

FE-SDMD was characterized by increased ceramides (CER), diacylglycerides (DAG), triacylglycerides (TG), sphingomyelins (SM), bis-monoacylglycerol phosphates (BMP), cholestone, and fatty-acyl amino acids (FAAA). DAG, CER, and BMP were the strongest predictors of depression severity and physiosomatic symptoms, whereas cholestone, CER, and SM predicted suicidal behaviors. These lipid modules, together with lowered LCAT and increased ONS, explained substantial variance in depression severity (46.4%), physiosomatic symptoms (42.4%), cognitive-affective symptoms (37.9%), suicidal behaviors (30.1%), insomnia (32%), and anxiety (19.5%). ACEs and NLEs were strongly associated with CER (p < 0.001), DAG (p < 0.01), and cholestone (p < 0.01), revealing coordinated lipidomic networks within a systems biology framework.

CONCLUSION:

Early-stage MDD is characterized by lipid dysregulations, which are linked to psychosocial stress exposure, oxidative stress and attenuated reverse cholesterol transport. These lipid modules identify biologically functional pathways associated with early disease and may inform the development of future therapeutic strategies.

01 Oct 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Integrated experimental and computational study of oxime-based derivatives: Antiproliferative evaluation, gene expression, DNA minor groove binding, detailed DFT, docking, and molecular dynamics analyses

Article

Author: Dehghanian, Effat ; Akkoc, Senem ; Panahande, Zahra ; Goodarzi, Mohammad ; Mohammadi Ziarani, Ghodsi ; Reiisi, Somayeh ; Feizi-Dehnayebi, Mehran

In this study, two oxime-based compounds, DAG and DAF, were synthesized and investigated using experimental, spectroscopic, biological, and computational approaches. The biological potential of the compounds was evaluated using MTT assays in normal HUVEC cells and HeLa cervical cancer cells. While both molecules exhibited low cytotoxicity toward normal cells, they demonstrated dose- and time-dependent antiproliferative activity against HeLa cells, with DAF showing slightly lower IC₅₀ values compared to DAG. Gene expression analysis further revealed upregulation of pro-apoptotic markers (CASP3 and CASP8) and downregulation of the anti-apoptotic gene BCL-2, suggesting the involvement of caspase-dependent apoptotic pathways, particularly in DAF-treated cells. The interaction of DAG and DAF with CT-DNA was explored using fluorescence spectroscopy, molecular docking, and molecular dynamics simulations. Fluorescence quenching studies indicated a static quenching mechanism and suggested a groove-binding mode rather than classical intercalation. Binding constant analysis revealed moderate DNA affinity, and DAF exhibited stronger interaction. Docking simulations supported minor groove binding stabilized mainly by hydrogen bonding interactions, while 150 ns MD simulations confirmed structural stability of the ligand+DNA complexes. DFT calculations provided insight into electronic structure, frontier molecular orbitals, charge distribution, MEP/ESP surfaces, RDG analysis, ELF, LOL, and quantum reactivity descriptors. ADME-Tox predictions confirmed compliance with Lipinski's RO5, acceptable solubility and lipophilicity, and absence of predicted toxicity risks. The results identify DAF as a promising DNA-interacting anticancer candidate with favorable pharmacokinetic and safety profiles.

01 Sep 2026·FOOD CHEMISTRY

Structure and antioxidant characteristics of diacylglycerol-based oleogels: A comparison with triacylglycerol systems

Article

Author: Wang, Xiuxiu ; Xu, Tongcheng ; Jia, Min ; Zhang, Xiaoqing ; Yue, Hao ; Li, Baorui ; Du, Fangling ; Zong, Aizhen

This study compared the effects of γ-oryzanol/β-sitosterol combined with monoglyceride (MAG) as composite gelators on soybean diacylglycerol (DAG) and triacylglycerol (TAG)-based oleogels. Results showed that TAG and DAG systems formed stable oleogels with high mechanical strength at γ-oryzanol/β-sitosterol concentrations of 4% and 8%, respectively. The subsequent addition of 1% MAG significantly reduced gel hardness (more pronounced in DAG), while the oil-binding capacity remained largely unaffected. Microstructural and FTIR analyses revealed that MAG transformed the crystal shape of DAG and TAG-based oleogels from a needle-like arrangement to clustered networks, and the intermolecular interactions were primarily driven by van der Waals forces. Accelerated oxidation demonstrated that while DAG exhibited higher oxidation rates than TAG in liquid and oleogels, the DAG composite gel displayed enhanced oxidative stability compared to γ-oryzanol/β-sitosterol only systems. These findings clarify the differences between DAG and TAG based oleogels, demonstrating the potential for MAG-phytosterol composite oleogels in functional foods.

News (Medical) associated with Dianhydrodulcitol

23 Sep 2025

·www.globenewswire.com

Innovate GBM’s 2025 Investment Playbook Year to Date Review: Building a New Market for Brain Cancer Investments and Breakthroughs

LOS ANGELES, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Innovate GBM, a 501(c)(3) nonprofit dedicated to transforming the landscape of brain tumor research, investment, and treatment, has released its 2025 Year-to-Date Impact Report, showcasing a bold new approach to solving some of oncology’s most stubborn and underfunded problems: glioblastoma multiforme (GBM) and other brain tumors. Built in memory of Sanam Thukral, DVM, a young veterinarian who passed away in 2024 following a 30-month battle with GBM, Innovate GBM has grown from a grassroots support group into a globally connected movement accelerating momentum in one of oncology’s most neglected fields. Rather than relying on traditional philanthropy or government grants, the organization is executing a capital markets driven playbook to fuel progress in a field long ignored by mainstream funders. Brain cancer research has too often been slowed by disconnected systems and isolated efforts, while other diseases have moved forward through clearer, more structured pipelines. Through an independent, investor-driven Ecosystem, Innovate GBM is channeling private capital, supporting public-company pathways, and engaging in high-level policy work to provide more clear treatment pathways. Most importantly, Innovate GBM is bringing physicians, researchers, advocates, regulators, investors, and companies into one coordinated network that works side by side to build a stronger path toward progress. Despite GBM’s lethality, accounting for just 1.5% of cancers but over 3.4% of cancer deaths, federal funding for brain tumor research has declined in recent years. “This isn’t just about the funding sources,” said Kush Thukral, Co-Executive Director of Innovate GBM. “it’s about changing the architecture of how investment, innovation, and urgency come together in the brain tumor space.” The Ecosystem is growing stronger. Since January 2025, Innovate GBM and its Community have achieved milestones such as: NASDAQ Closing Bell Ceremony: On June 12, 2025, Innovate GBM rang the NASDAQ Closing Bell in Times Square in honor of GBM patients and the broader brain tumor community, signaling a new era of urgency and visibility for the field.40+ Community Members with Zero Dollar Fundraising: The organization remains entirely bootstrapped, driven not by donations, but by a committed internal operations team and a coalition of over 40 top tier Community Members spanning clinical, academic, venture, and advocacy sectors.Catalyzing Investment: Helped drive $170M+ in committed capital across 9+ companies in the brain tumor pipeline: Paxalisib, SurVaxM, VXM01, NEO100, TTX-MC138, VAL-083, CHI3L1, CeCava, and DCVax–L.Joined a brain tumor investment syndicate in collaboration with leading partners including the Brain Tumor Investment Fund, Sontag Foundation, White Lion GBM Innovation Fund, BrightEdge, Alliance for Cancer Gene Therapy, MEDA Angels, Lindonlight, Pathway Bioventures, and DeepWork Capital. Policy and Legislative Advocacy: Advanced support for the BRAIN Act (S.4739) alongside the National Brain Tumor Society, spotlighting bipartisan federal action to improve care and innovation pathways for brain cancer patients.Ecosystem Partnerships: Strengthened working relationships with members from top institutions including the National Brain Tumor Society, Global Coalition for Adaptive Research, GBM Agile, OSR Holdings, UCLA, Brown University, USC, StacheStrong, Glioblastoma Research Organization, Landmark Bioventures, Spanios Lab, Valkyrie Clinical Trials, Penn Medicine, and Northwestern University. Every breakthrough in brain cancer is the result of one more shot on goal. Innovate GBM’s playbook doesn’t just create hope, it helps expand the chances for patients and families to see better options in their lifetime. We are not the first and we will not be the last, but we are proud to stand shoulder to shoulder with every patient, family, researcher, and advocate fighting this disease. Co-Executive Director Yash Thukral, JD, reflected, “We are building more than a market, we are building momentum. Every dollar, every investment, and every partnership adds up to a new architecture where cures are no longer impossible, but inevitable.” To support Innovate GBM’s efforts to drive progress across the brain tumor Ecosystem, please consider making a donation at: https://innovategbm.org/donate/ About Innovate GBMInnovate GBM is a 501(c)(3) nonprofit organization that is curating an ecosystem for innovation amongst researchers, physicians, and investors to speed up treatment for Glioblastoma. By uniting key nodes of the healthcare ecosystem - physicians, researchers, companies, regulators, investors, and advocates - Innovate GBM builds the platforms and partnerships needed to accelerate progress in glioblastoma and related brain cancers. Our Community members span across a variety of organizations, such as the National Brain Tumor Society, the Brain Tumor Investment Fund, the Global Coalition for Adaptive Research, OSR Holdings, Inc, University of California Los Angeles, Brown University, University of Southern California, Spanios Labs, Penn Medicine, and Northwestern University. Media Contact: Katelyn Laufer, Head of Marketing operations@innovategbm.org www.innovategbm.org Community Contact: Harrison Seidner, PhD WaterSeid Partners, Inc. harrison@waterseid.com

14 Feb 2024

·www.prnewswire.com

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2023, and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced the initiation of an open label 15-patient study in cutaneous metastatic breast cancer (CMBC) patients which is evaluating REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate (bORR) (complete response or partial response) of the target treatment fields at any time from treatment up to, and including, week 24. The majority of the costs to run this study will be covered by the $2.0 million Small Business Innovation Research (SBIR) grant Kintara was awarded from the National Institutes of Health (NIH). (February 2024) Announced that Kintara's Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and has engaged Ladenburg Thalmann & Co. Inc. to act as financial advisor for this process. (December 2023) Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. As a result, Kintara terminated the development of VAL-083 and turned its focus to its REM-001 program. (October 2023) "We are pleased to have recently initiated our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. "We have strengthened our balance sheet primarily with net proceeds from our at-the-market (ATM) facility and aggressive cost-cutting efforts. We continue to evaluate strategic options with the goal of maximizing shareholder value." SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 SECOND QUARTER ENDED DECEMBER 31, 2023 As of December 31, 2023, Kintara had cash and cash equivalents of approximately $0.7 million. From January 1, 2024, to February 12, 2024, the Company has received net proceeds of approximately $6.1 million from the sale of common stock, primarily from its ATM facility. For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share, compared to a net loss of approximately $3.5 million, or $2.10 per share, for the three months ended December 31, 2022. The decreased net loss for the three months ended December 31, 2023, compared to the three months ended December 31, 2022, was largely attributed to lower research and development expenses which was primarily due to lower clinical development costs. General and administrative costs were also lower during the same period primarily due to a reduction in personnel. Kintara's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company's website at: . ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing therapeutics for clear unmet medical needs with reduced risk development programs. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. For more information, please visit or follow us on X at @Kintara_Thera, Facebook and LinkedIn. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's REM-001 15-patient clinical trial in CMBC patients; the topline results of the GBM AGILE Study; and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the status of the Company's clinical trials; the topline results of the GBM AGILE Study; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Investors Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

Financial StatementPhase 3Radiation Therapy

13 Nov 2023

·www.prnewswire.com

Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of care used to treat glioblastoma. With this study outcome, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. In addition to focusing on its REM-001 program, Kintara will evaluate a wide range of strategic options aimed at potentially maximizing shareholder value. (October 2023) Awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical development of REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent for the treatment of cutaneous metastatic breast cancer (CMBC). (June 2023) "We are looking forward to enrolling the first patient in our 15 patient REM-001 study for cutaneous metastatic breast cancer, a disease with little or no current treatment options" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. "The majority of study expenses will be covered by the $2 million National Institutes of Health grant we were awarded to support the further development of REM-001. We have undertaken efforts to significantly cut costs and are continuing to evaluate strategic options with the goal of maximizing shareholder value." SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 FIRST QUARTER ENDED SEPTEMBER 30, 2023 As of September 30, 2023, Kintara had cash and cash equivalents of approximately $0.2 million. In November 2023, the Company has received net proceeds of approximately 1.0 million from the sale of common stock, primarily from its at-the-market (ATM) facility. For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022. The decreased net losses for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 was largely due to lower research and development expenses, primarily lower clinical development costs. General and administrative costs were also lower during the same period primarily due to reduced level of staffing. Kintara's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company's website at: . ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara develops therapeutics for clear unmet medical needs with reduced risk development programs. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. For more information, please visit or follow us on X at @Kintara_Thera, Facebook and Linkedin. SAFE HARBOR STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials; the topline results of the GBM AGILE Study; and the Company's review of strategic alternatives. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the status of the Company's clinical trials; the topline results of the GBM AGILE Study; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; and global unrest. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2023, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K. CONTACTS Investors Robert E. Hoffman Kintara Therapeutics [email protected] SOURCE Kintara Therapeutics

Financial StatementRadiation Therapy

100 Deals associated with Dianhydrodulcitol

External Link

KEGG	Wiki	ATC	Drug Bank
D10623	-	L01	DB12873

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lung Cancer	China	Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.	13 Sep 2020
Philadelphia chromosome positive chronic myelogenous leukemia	China	Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd.	13 Sep 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 3	United States	Kintara Therapeutics, Inc.	27 Oct 2017
Recurrent Glioblastoma	Phase 3	United States	Kintara Therapeutics, Inc.	27 Oct 2017
Recurrent Platinum-Resistant Ovarian Carcinoma	Phase 2	United States	Kintara Therapeutics, Inc.	01 Mar 2021
Recurrent Malignant Glioma	Phase 2	United States	Kintara Therapeutics, Inc.	01 Oct 2011
Ovarian Cancer	Phase 2	United States	Kintara Therapeutics, Inc.	-
Hematologic Neoplasms	Clinical	United States	National Cancer Institute	-
Solid tumor	Clinical	United States	National Cancer Institute	-
Diffuse Intrinsic Pontine Glioma	Preclinical	United States	Kintara Therapeutics, Inc.	21 Apr 2019
Medulloblastoma	Preclinical	United States	Kintara Therapeutics, Inc.	23 Feb 2016
Non-Small Cell Lung Cancer	Preclinical	Canada	Kintara Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02717962 (CTNI-73, SNO2024)	Phase 2	Glioblastoma Multiforme PTEN \| EGFR \| TP53	34	VAL-083 30 mg/m2	dtxpvjaurg(zmkdrvpqfb) = sbekckrlmi hleugjrcad (lnqwsdloru, 13.3 - 19.0) View more	Negative	11 Nov 2024
NCT03138629 (CTNI-72, SNO2024)	Not Applicable	Recurrent Glioblastoma TERT \| PTEN \| TP53 ... View more	30	VAL-083 30 mg/m2/day	pkrjtpbriw(dxkhxxmzkz) = The most frequent adverse events were consistent with prior experience, i.e., neutropenia lpsiigvopn (accirnvwdk ) View more	Positive	11 Nov 2024
NCT03138629 (CTNI-71, SNO2024)	Not Applicable	Ependymoma \| Diffuse Midline Glioma \| Astrocytoma, IDH-Mutant IDHwt \| MAP2K1 \| ATRX ... View more	4	VAL-083	afflfbptmk(abeansntzg) = dcisavhbjt vxhokdstah (haswandsjv )	Positive	11 Nov 2024
NCT03138629 (AACR2023) Manual	Not Applicable	Recurrent Glioblastoma unmethylated MGMT promoter \| IDH wild type \| MSH6 mutation ... View more	24	VAL-083 30mg/m2 ± Bevacizumab	dwrgmupccj(nnfixsoyha) = VAL-083 was well tolerated and the main adverse events were consistent with prior experience, i.e., thrombocytopenia and neutropenia. yfltxpyyvg (cascrzpgyu )	Positive	14 Apr 2023
				VAL-083 30mg/m2 ± Bevacizumab (Patients without multifocal disease)
NCT03138629 (DDDR-36, SNO2022)	Not Applicable	Recurrent Glioblastoma unmethylated MGMT promoter \| IDH-WT \| TERT promoter mutation ... View more	14	VAL-083	gnyvwgylip(rcafmbsdmq) = The main adverse event was thrombocytopenia consistent with prior experience xxiuccpfvt (siyfjvwxeu )	-	14 Nov 2022
NCT03050736 (CTNI-21, SNO2021)	Phase 2	Glioblastoma Multiforme MGMT-unmethylated	29	VAL-083 20 mg/m2/day	jeffcwcvzw(pcvzlkhlai) = Sixteen (16/29; 55.2%) patients had died ouedbvprny (lrfwaotarl ) View more	Positive	12 Nov 2021
				VAL-083 30 mg/m2/day
NCT02717962 (PRNewswire) Manual	Phase 2	Glioblastoma	89	VAL-083 (40 mg/m2/day)	dtqhuvkgvm(msynauqemf) = lsmcmhximb acaomfyemt (coupfxdrgw, 6.1 - 9.0)	Positive	01 Jul 2021
				VAL-083 (receiving the treatment dose of 30 mg/m2/day on days 1, 2 and 3 of a 21-day cycle)	dtqhuvkgvm(msynauqemf) = cbbsecuanz acaomfyemt (coupfxdrgw, 5.9 - 9.9) View more
NCT03050736 \| NCT02717962 (AACR2020)	Phase 2	Glioblastoma Multiforme Second line	-	VAL-083	btutwjmtmf(rigavqkyne) = moabyragys gqnobiytlj (jbvveimqur )	Positive	15 Aug 2020
				VAL-083+Bevacizumab	btutwjmtmf(rigavqkyne) = vzljqnvssb gqnobiytlj (jbvveimqur )
NCT01478178 (DLM-10-001, ASCO2018)	Phase 1/2	Glioblastoma	45	Clinically active dose of VAL-083	sxfwnrfbet(dlgaodnsvg) = jfsannogjp gqahooezwa (mxnwntqgfd, 3.1 - 9.6)	Positive	01 Jun 2018
				Inactive dose of VAL-083	sxfwnrfbet(dlgaodnsvg) = tzmgddyjzs gqahooezwa (mxnwntqgfd )
NCT01478178 (AACR2016)	Phase 1/2	Recurrent Glioblastoma	55	VAL-083	tlurvumbpg(qwgvsozwvn) = Observed myelosuppression is mild, with the exception of 1 patient previously treated with CCNU who developed grade 4 thrombocytopenia saklescrwv (bpaqdrifgv ) View more	Positive	15 Jul 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis